These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16713265)

  • 41. Molecular modelling and biological evaluation of a series of hydroxylated benzylideneanilines and benzylamines designed as tyrosine kinase inhibitors.
    Solomons KR; Lieberman HF; Groundwater PW; Hibbs DE; Hursthouse MB
    Anticancer Drug Des; 1997 Dec; 12(8):635-47. PubMed ID: 9448703
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure-activity relationship study of novel necroptosis inhibitors.
    Teng X; Degterev A; Jagtap P; Xing X; Choi S; Denu R; Yuan J; Cuny GD
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5039-44. PubMed ID: 16153840
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and antiproliferative activity of substituted diazaspiro hydantoins: a structure-activity relationship study.
    Ananda Kumar CS; Prasad SB; Vinaya K; Chandrappa S; Thimmegowda NR; Ranganatha SR; Swarup S; Rangappa KS
    Invest New Drugs; 2009 Apr; 27(2):131-9. PubMed ID: 18607541
    [TBL] [Abstract][Full Text] [Related]  

  • 44. QSAR characterization of new synthesized hydantoins with antiproliferative activity.
    Tot K; Lazić A; Božić B; Mandić A; Djaković Sekulić T
    Biomed Chromatogr; 2019 Aug; 33(8):e4539. PubMed ID: 30927290
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 5-Benzylidene-hydantoin is a new scaffold for SIRT inhibition: From virtual screening to activity assays.
    Sacconnay L; Ryckewaert L; Randazzo GM; Petit C; Passos Cdos S; Jachno J; Michailovienė V; Zubrienė A; Matulis D; Carrupt PA; Simões-Pires CA; Nurisso A
    Eur J Pharm Sci; 2016 Mar; 85():59-67. PubMed ID: 26791955
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 5,5-disubstituted hydantoins: syntheses and anti-HIV activity.
    Comber RN; Reynolds RC; Friedrich JD; Manguikian RA; Buckheit RW; Truss JW; Shannon WM; Secrist JA
    J Med Chem; 1992 Sep; 35(19):3567-72. PubMed ID: 1404236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of potency of hydantoins in metaphase arrest and inhibition of microtubular polymerization.
    MacKinney AA; Vyas R; Mueller C; Gorder C
    Mol Pharmacol; 1980 Mar; 17(2):275-8. PubMed ID: 7393208
    [No Abstract]   [Full Text] [Related]  

  • 48. [Pharmacologic properties of new 5-benzylidene derivatives of 3-m-nitrophenyl-2-thiohydantoin].
    Kleinrok Z; Kozicka M; Tobiasz-Otrebska K; Sermak W
    Ann Univ Mariae Curie Sklodowska Med; 1985; 40():169-76. PubMed ID: 3917076
    [No Abstract]   [Full Text] [Related]  

  • 49. New anti-mycobacterial hydantoins.
    Zaidi SM; Satsangi RK; Nasir PK; Agarwal R; Tiwari SS
    Pharmazie; 1980 Dec; 35(12):755-6. PubMed ID: 7208576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis of new 1-[5-(substituted phenoxymethyl)-1,3,4-oxadiazol-2-yl] -5-(substituted benzylidene)hydantoins as potential anthelminthic agents.
    Shukla JS; Agarwal KK
    Arch Pharm (Weinheim); 1983 Sep; 316(9):796-801. PubMed ID: 6639305
    [No Abstract]   [Full Text] [Related]  

  • 51. [Structure and effect of biologically active compounds. Part 7. Barbituric acid derivatives, hydantoins and related compounds].
    PERKOW W
    Arzneimittelforschung; 1960 Apr; 10():284-8. PubMed ID: 14431876
    [No Abstract]   [Full Text] [Related]  

  • 52. [Relation between the chemical structure and the anticonvulsive acts of some brominated hydantoins].
    FEER H; WASER PG
    Helv Physiol Pharmacol Acta; 1956; 14(1):29-36. PubMed ID: 13331325
    [No Abstract]   [Full Text] [Related]  

  • 53. [Relation of anti-spastic properties and toxicity to the chemical structure of thiohydantoin and rhodanine derivatives].
    ZAPADNIUK VI
    Farm Zh; 1962; 17():36-42. PubMed ID: 14009836
    [No Abstract]   [Full Text] [Related]  

  • 54. [Studies with estrogens and hydantoins on the vascular connective tissue apparatus in a rabbit experiment].
    SCHLEGEL D; TRIADAN H
    Med Monatsschr; 1961 Feb; 15():88-90. PubMed ID: 13747774
    [No Abstract]   [Full Text] [Related]  

  • 55. Studies in possible oral hypoglycaemic agents. II. Synthesis of hydantoins and hydantoic esters by alternate methods.
    DHAR DN; POPLI SP; DHAR ML
    J Sci Ind Res (C); 1961 May; 20C():145-7. PubMed ID: 13722426
    [No Abstract]   [Full Text] [Related]  

  • 56. Inhibition of degradation of insulin-I131 in vivo.
    ELGEE NJ; WILLIAMS RH
    Proc Soc Exp Biol Med; 1954 Oct; 87(1):67-70. PubMed ID: 13224679
    [No Abstract]   [Full Text] [Related]  

  • 57. 5-Trifluoromethyl hydantoins.
    LOEV B; FLORES M
    J Pharm Sci; 1961 Sep; 50():800. PubMed ID: 13763121
    [No Abstract]   [Full Text] [Related]  

  • 58. [On the preparation of 5-antipyrylhydantoins].
    BODENDORF K; SCHOELZEL N
    Mitt Dtsch Pharm Ges Pharm Ges DDR; 1959 Oct; 29():558-64. PubMed ID: 13858536
    [No Abstract]   [Full Text] [Related]  

  • 59. [Anticonvulsive activity of diphenylhydantoine studied on the rat with the Swinyard test. Characteristic difference between male & female specimens].
    BERTRAND I; QUIVY D; GAYET-HALLION T
    Arch Int Pharmacodyn Ther; 1951 Oct; 88(1):106-14. PubMed ID: 14934346
    [No Abstract]   [Full Text] [Related]  

  • 60. [Studies on the aspartic acid antagonism of 2-thio-5-acetylhydantoin].
    CSALAY L; HARMOS G; KEMENY T; PERENYI L; SOS J
    Kiserl Orvostud; 1956 Jul; 8(4):390-7. PubMed ID: 13377580
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.